The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy-Reference-Cited by-同舟云学术

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy

Published:2023 Issue: Volume:37 Page:100767
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Proulx-Rocray Francis^ORCID,Routy Bertrand,Nassabein Rami,Belkaid Wiam,Tran-Thanh Danh,Malo Julie,Tonneau Marion,Ouarzadi Omar El,Florescu Marie,Tehfe Mustapha,Blais Normand^ORCID

Funder

University of Montreal

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. SEER Cancer Statistics Review, 1975-2018;Howlader,2021

3. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;N. Engl. J. Med.,2016

4. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer;Gandhi;N. Engl. J. Med.,2018

5. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;N. Engl. J. Med.,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current perspectives of KRAS in non-small cell lung cancer;Current Problems in Cancer;2024-08

2. TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations;Frontiers in Oncology;2024-04-22